Russell Investments Group Ltd. Sells 9,956 Shares of Simulations Plus, Inc. (NASDAQ:SLP)

Russell Investments Group Ltd. cut its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 5.4% during the fourth quarter, HoldingsChannel reports. The firm owned 172,878 shares of the technology company’s stock after selling 9,956 shares during the period. Russell Investments Group Ltd.’s holdings in Simulations Plus were worth $7,736,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Illinois Municipal Retirement Fund grew its position in shares of Simulations Plus by 2.8% during the 4th quarter. Illinois Municipal Retirement Fund now owns 9,647 shares of the technology company’s stock worth $432,000 after buying an additional 263 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC grew its holdings in Simulations Plus by 194.5% during the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,487 shares of the technology company’s stock worth $62,000 after acquiring an additional 982 shares in the last quarter. Canton Hathaway LLC increased its position in Simulations Plus by 25.0% during the 4th quarter. Canton Hathaway LLC now owns 5,000 shares of the technology company’s stock valued at $224,000 after purchasing an additional 1,000 shares during the period. Campbell & CO Investment Adviser LLC raised its holdings in shares of Simulations Plus by 21.7% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 6,089 shares of the technology company’s stock valued at $254,000 after purchasing an additional 1,084 shares in the last quarter. Finally, Cook Wealth Management Group LLC lifted its position in shares of Simulations Plus by 9.5% in the 3rd quarter. Cook Wealth Management Group LLC now owns 13,922 shares of the technology company’s stock worth $581,000 after purchasing an additional 1,204 shares during the period. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $45.95, for a total transaction of $919,000.00. Following the completion of the transaction, the director now owns 3,580,857 shares in the company, valued at approximately $164,540,379.15. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 20.90% of the company’s stock.

Simulations Plus Stock Up 0.7 %

Shares of SLP stock opened at $48.54 on Wednesday. The firm has a market cap of $970.07 million, a price-to-earnings ratio of 91.58 and a beta of 0.68. Simulations Plus, Inc. has a 52-week low of $32.69 and a 52-week high of $52.69. The company’s 50 day moving average is $44.28 and its 200 day moving average is $41.32.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Wednesday, April 3rd. The technology company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.02. The business had revenue of $18.31 million for the quarter, compared to the consensus estimate of $17.31 million. Simulations Plus had a return on equity of 7.95% and a net margin of 16.22%. The business’s revenue was up 16.2% compared to the same quarter last year. During the same period last year, the business posted $0.20 EPS. Analysts anticipate that Simulations Plus, Inc. will post 0.67 EPS for the current fiscal year.

Simulations Plus Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, May 6th. Shareholders of record on Monday, April 29th were given a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a dividend yield of 0.49%. The ex-dividend date of this dividend was Friday, April 26th. Simulations Plus’s payout ratio is 45.28%.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.